Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia

Abstract

The version presented here may differ from the published version. If citing, you are advised to consult the published version for pagination, volume/issue and date of publication Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia (Review)

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital

“…There is heterogeneity in prescribing rFVIIa and its use does not conform to European guidelines [1]. Controversy continues about the merits of using off-licence rFVIIa at all [2]. …”

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital

“…There is heterogeneity in prescribing rFVIIa and its use does not conform to European guidelines [1]. Controversy continues about the merits of using off-licence rFVIIa at all [2]. …”

Clinical and Surgical Strategies for Avoiding or Reducing Allogeneic Blood Transfusions

“…Studies demonstrate the effectiveness of the human fibrinogen concentrate [ 18 ] and the recombinant factor VIIa [ 19 ] for controlling greater bleeding during surgery, and thereby, avoiding transfusions of plasma and/or platelets. In our case, these medications also proved to be effective hemostatic for controlling bleeding and avoiding the use of hemotransfusions.…”

Late Postoperative Segmental Lung Infarction After Use of Recombinant Activated Factor VII to Achieve Hemostasis

“…7 Lin et al conducted a meta-analysis of 26 randomized controlled trials that analyzed the use of rFVIIa in patients without hemophilia. 8 A total of 1137 patients were given rFVIIa as an off-label prophylactic dose, and 2538 patients were given rFVIIA as an off-label therapeutic dose. Doses ranged from 5 lg/kg to many doses that totaled 360 lg/kg.…”

“…The researchers were unable to determine what should be a recommended dose for off-label use of rFVIIa. 8 Despite this, the precise etiology of the current patient's considerable postoperative complications is elusive. The use of rFVIIa may be the primary cause; however, rFVIIa has been given many times in past cases, such as for patients with penetrating or blunt trauma, and these patients had had no postoperative complications.…”

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital

“…There is heterogeneity in prescribing rFVIIa and its use does not conform to European guidelines [1]. Controversy continues about the merits of using off-licence rFVIIa at all [2]. …”

Clinical and Surgical Strategies for Avoiding or Reducing Allogeneic Blood Transfusions

“…Studies demonstrate the effectiveness of the human fibrinogen concentrate [ 18 ] and the recombinant factor VIIa [ 19 ] for controlling greater bleeding during surgery, and thereby, avoiding transfusions of plasma and/or platelets. In our case, these medications also proved to be effective hemostatic for controlling bleeding and avoiding the use of hemotransfusions.…”

Late Postoperative Segmental Lung Infarction After Use of Recombinant Activated Factor VII to Achieve Hemostasis

“…7 Lin et al conducted a meta-analysis of 26 randomized controlled trials that analyzed the use of rFVIIa in patients without hemophilia. 8 A total of 1137 patients were given rFVIIa as an off-label prophylactic dose, and 2538 patients were given rFVIIA as an off-label therapeutic dose. Doses ranged from 5 lg/kg to many doses that totaled 360 lg/kg.…”

“…The researchers were unable to determine what should be a recommended dose for off-label use of rFVIIa. 8 Despite this, the precise etiology of the current patient's considerable postoperative complications is elusive. The use of rFVIIa may be the primary cause; however, rFVIIa has been given many times in past cases, such as for patients with penetrating or blunt trauma, and these patients had had no postoperative complications.…”

Analysis of the off-licence use of recombinant activated factor VII for patients with uncontrolled haemorrhage in a UK tertiary referral hospital

“…There is heterogeneity in prescribing rFVIIa and its use does not conform to European guidelines [1]. Controversy continues about the merits of using off-licence rFVIIa at all [2]. …”

Clinical and Surgical Strategies for Avoiding or Reducing Allogeneic Blood Transfusions

“…Studies demonstrate the effectiveness of the human fibrinogen concentrate [ 18 ] and the recombinant factor VIIa [ 19 ] for controlling greater bleeding during surgery, and thereby, avoiding transfusions of plasma and/or platelets. In our case, these medications also proved to be effective hemostatic for controlling bleeding and avoiding the use of hemotransfusions.…”

Late Postoperative Segmental Lung Infarction After Use of Recombinant Activated Factor VII to Achieve Hemostasis

“…7 Lin et al conducted a meta-analysis of 26 randomized controlled trials that analyzed the use of rFVIIa in patients without hemophilia. 8 A total of 1137 patients were given rFVIIa as an off-label prophylactic dose, and 2538 patients were given rFVIIA as an off-label therapeutic dose. Doses ranged from 5 lg/kg to many doses that totaled 360 lg/kg.…”

“…The researchers were unable to determine what should be a recommended dose for off-label use of rFVIIa. 8 Despite this, the precise etiology of the current patient's considerable postoperative complications is elusive. The use of rFVIIa may be the primary cause; however, rFVIIa has been given many times in past cases, such as for patients with penetrating or blunt trauma, and these patients had had no postoperative complications.…”